Evaluation of tumor gene expression profile and Gleason score in patients with metastatic prostate cancer.

person Carla Simone Moreira Freitas Hospital do Cancer de Muriae, Muriae, Minas Gerais, Brazil info_outline Carla Simone Moreira Freitas, Thais Almeida Marques da Silva, Fabiana Rocha Silva, Aleida Nazareth Soares

Authors person Carla Simone Moreira Freitas Hospital do Cancer de Muriae, Muriae, Minas Gerais, Brazil info_outline Carla Simone Moreira Freitas, Thais Almeida Marques da Silva, Fabiana Rocha Silva, Aleida Nazareth Soares Organizations Hospital do Cancer de Muriae, Muriae, Minas Gerais, Brazil, Faculdade Santa Casa de BH, Belo Horizonte, Brazil Abstract Disclosures Research Funding No funding sources reported Background: The Gleason Score (GS) is a fundamental prognostic indicator in prostate adenocarcinoma. Despite this significant clinical relevance, the determinants underlying disease aggressiveness in relation to GS remain largely unknown. To explore gene expression profiles among patients diagnosed with metastatic prostate adenocarcinoma, considering GS variation. Methods: This study is prospective in nature and was approved by CONEP-SCBH-CAAE 42638620.3.0000.5138. The study included 30 patients with histologically confirmed metastatic prostate adenocarcinoma who had not undergone any treatment. Patients were stratified into two distinct cohorts based on GS: low GS (GS <8) and high GS (GS ≥ 8). This design allowed for a more in-depth analysis of the associations between gene expression profiles and GS variations in the context of metastatic prostate adenocarcinoma. Results: The data show that 26.7% of patients (n=8) had a GS lower than 8, while 73.3% (n=22) had a GS equal to or greater than 8. In patients with a GS lower than 8, genetic profile analysis revealed that the ATM gene was expressed in three patients and the BRCA2 and TP53 genes were detected in one patient (n=1 for each gene). In relation to patients with GS equal to or greater than 8, the TP53 gene was expressed in 7 patients; the BRCA2, CHECK2, FANCL, RAD51C and RAD54L genes were expressed in only one patient (n=1 for each gene). These results indicate a more prominent expression of TP53 in patients with high GS, suggesting a relationship between the expression of this gene and the aggressiveness of metastatic prostate cancer with GS ≥8. In the sample, no positivity was observed for the BRCA1, CDK12, CHECK1, PALB2, PPP2R2A, RAD51B and RAD51D genes. Conclusions: The results show that metastatic prostate cancer patients with GS ≥8 exhibit elevated TP53 gene expression. The current sample of 30 patients provides preliminary insight, but the statistical robustness of these associations could be improved with a larger cohort. Carrying out subsequent studies with a broader sample will allow for a more reliable validation of the observed trends, contributing to a more comprehensive understanding of the associations between the analyzed variables and gene expression in patients with metastatic prostate carcinoma. Therefore, the interpretation of the results presented must be carried out with caution, considering the need for a more substantial sample size to verify and consolidate possible associations identified. Clinical trial information: CAAE42638620.3.0000.5138.

Clinical